Enhancing mitochondrial proteolysis alleviates alpha-synuclein-mediated cellular toxicity.

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Parkinson's disease (PD) involves mitochondrial dysfunction and alpha-synuclein (α-Syn) aggregation.
• The precise mechanisms linking α-Syn to mitochondrial damage are not fully understood.

Purpose of the Study:

• To investigate the role of α-Syn import into mitochondria in causing cellular dysfunction.
• To identify potential therapeutic targets for α-synucleinopathies.

Main Methods:

• Investigated α-Syn import into mitochondria in yeast, human cells, and a transgenic mouse model.
• Assessed the impact of α-Syn on mitochondrial function, including mtDNA, membrane potential, and cellular fitness.
• Examined the role of mitochondrial proteases (NLN, PITRM1) in α-Syn degradation.
• Tested the therapeutic potential of enhancing mitochondrial proteolysis.

Main Results:

• α-Syn is constitutively imported into mitochondria in various cell types and accumulates with age in a PD mouse model.
• Undegraded α-Syn in the mitochondrial matrix disrupts respiratory chain complexes, leading to mtDNA loss and reduced cellular fitness.
• Increasing mitochondrial protease levels mitigated α-Syn-induced defects in yeast, human cells, and primary neurons.

Conclusions:

• Directly links α-Syn import into mitochondria to cellular toxicity in Parkinson's disease.
• Highlights mitochondrial proteolysis as a promising therapeutic avenue for α-synucleinopathies.